PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Dirk Beher et al.

Serial No.:

To Be Assigned

Case No.: T1615YP

US Nat'l Filing Date:

May 24, 2006

Int'l Appl'n No.

PCT/GB2004/004985

Int'l Filing Date:

25 November 2004

For:

1-ALKYL-3-THIO-SUBSTITUTED INDOLE-2-ALKYNOIC ACIDS USEFUL FOR THE TREATMENT OF ALZHEIMER'S

DISEASE AND RELATED CONDITIONS

MAIL STOP PCT Commissioner for Patents P.O. BOX 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT EXPRESS MAIL NO.

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail "Post Office to Addressee" on the above date in an envelope addressed

Commissioner for Patents, P. O. Box 1450, Alexandria, Virginia 22313-1450

MAILED BY

DATE

Int'l Appl'n No.: Case No.: PCT/GB2004/004985

T1615YP

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

References A-D on the accompanying PTO 1440 form were cited in the International Search Report for this application. A copy of the International Search Report is enclosed with this Information Disclosure Statement.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application. Accordingly, it is believed that no fee is due. Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

John C. Todaro, Reg. No. 36,036

Attorney for Applicant

MERCK & CO., Inc. P.O. Box 2000 Rahway, New Jersey 07065-0907 (732) 594-0125

Date: May 24, 2006

Su	ubstitute for form 1449A/PTO			COMPLETE IF KNOWN			
I	INFORMATION DISCLOSURE			Application Number	To Be Assigned 1580286		
OT A TOP SERVE DAY A DRIVE A NOT				Filing Date			
5	STATEMENT BY APPLICANT			First Named Inventor	Dirk Beher		
	,			Group Art Unit	To Be Assigned		
	(use as many sheets as necessary)			Examiner Name	To Be Assigned		
Sheet	1	of	2	Attorney Docket Number	T1615YP		

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
	Α	2003/0082108		Mulshine et al.	05/01/2003		
	В	5,081,138		Gillard et al.	01/14/1992		
			\perp				
		,,,					

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.			ument Kind Code (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
	С		WO 00/02561		PCT	University of South Florida	01/20/2000	
							_	
Examin Signatu	er re					Date Considered		

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUBSTITUTE for PTO/SB/08A (07-05), Information Disclosure Statement by Applicant Patent and Trademerk Office: U.S DEPARTMENT OF COMMERCE

		-		COMPLETE IF KNOWN			
-	Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	To Be Assigned 6/500206				
COLATERATERIE DE A DEL LO ARIE				Filing Date	267 700 2 5 6		
3	STATEMENT BY APPLICANT		First Named Inventor	Dirk Beher			
				Group Art Unit	To Be Assigned		
	(use as many sheet.	s as n	ecessary)	Examiner Name	To Be Assigned		
Sheet	2	of	2	Attorney Docket Number	T1615YP		

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.				
	D	R. Frenette et al., "Substituted Indoles as Potent and Orally Active 5-Lipoxygenase Activating Protein (FLAP) Inhibitors," Bioorganic & Med. Chem. Letters, Vol. 9, pp. 2391-2396 (1999)				
,						
	_					
	1					

Examiner Signature	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.